ACVR1C and obesity due to melanocortin 4 receptor deficiency: We found that the anti-ALK7 treatment markedly reduces adiposity and markedly ameliorates obesity-associated metabolic disorders, thus implicating ALK7 as a promising target for obesity therapy.